Recombinant proteins market seen reaching $4.84 billion by 2030

The recombinant proteins market is projected to grow from $2.55 billion in 2025 to $4.84 billion by 2030, driven by personalized medicine, biologics and biomanufacturing investment. North America held the largest share in 2025 as companies and researchers expand use of recombinant proteins in therapeutics, diagnostics and drug development.

Why it matters: - The recombinant proteins market is positioned for sustained double-digit growth as biologics, personalized medicine and research demand expand. - The forecast points to a larger role for engineered proteins in drug development, diagnostics and advanced therapies. - The trend matters for biopharma companies, diagnostics developers and manufacturers building capacity for high-purity proteins.

What happened: - The Business Research Company published its Recombinant Proteins Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report pegs the market at $2.55 billion in 2025 and $2.89 billion in 2026. - The report projects the market will reach $4.84 billion by 2030, implying a 13.7% CAGR over the forecast period. - North America held the largest market share in 2025. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company also says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated trend analysis.

The details: - Recombinant proteins are engineered proteins created using recombinant DNA technology. - The process involves cloning a gene into a plasmid vector, usually downstream of a promoter region for expression. - Recombinant proteins are used in pharmaceutical manufacturing, protein-based polymers for drug delivery, antibodies and enzymes for treating diseases, protein scaffolds for tissue engineering and other biomedical applications. - Historical growth was driven by biologics-based drug development, rising autoimmune and chronic disease incidence, protein-based diagnostics, growing use of recombinant insulin and better expression system efficiency. - Future growth is expected to come from next-generation biologics, higher biomanufacturing investment, demand for personalized therapies, biosimilar development and broader use in research. - Emerging trends include therapeutic antibody production, stronger demand for recombinant enzymes, advances in protein engineering, expanded biologics manufacturing capacity and more focus on high-purity proteins. - Personalized medicine is a key driver because treatments are increasingly tailored to patients' genetic makeup and individual characteristics. - Recombinant proteins support personalized medicine by enabling treatments matched to individual molecular and genetic traits. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The forecast suggests the market is moving from a research and manufacturing niche into a broader platform for precision medicine and next-generation biologics. - North America's lead likely reflects its deep biotech base, stronger healthcare infrastructure and concentration of advanced drug development activity. - The rise in personalized treatments signals more demand for specialized proteins, especially in rare disease and targeted therapy pipelines.

What's next: - Market growth will likely track investment in biomanufacturing, biosimilars and protein engineering capabilities. - Demand should rise for recombinant enzymes, therapeutic antibodies and high-purity proteins used in both research and commercial production. - Companies and investors will watch regional expansion, especially outside North America, as adoption spreads across major global markets.

The bottom line: - Recombinant proteins are moving deeper into mainstream biotech, and the market's 13.7% CAGR forecast points to durable demand across medicine, research and manufacturing. - More information is available in the full report.